As more biosimilars enter the U.S. market, especially for the potentially curative oncology blockbusters, the competitive landscape is finally intensifying. In the wake of multiple biosimilar competitors for the same reference product, it’s important we understand the systems in which these products are being introduced. How are Integrated Delivery Networks, independent physician offices, medical centers, and hospitals preparing for and greeting biosimilars? Which best practices have healthcare practitioners put in place to ensure efficient usage, and where do hang-ups still exist?
In this e-book, experts from a wide range of settings of care explain their successful biosimilar implementation initiatives, the evolving healthcare treatment landscape, and which systemic barriers still must be overcome to improve education and uptake.